← Leaderboards
Michel Dupage
University Of California Berkeley
$4,220,441
Attributed
$5,025,752
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,025,752 · 5
By mechanism
DP2$2,355,000 · 1
R01$2,229,550 · 3
R21$441,202 · 1
Top collaborators
- Daniel A Portnoy2 shared
- David H Raulet1 shared
Most similar at University Of California Berkeley
Same institution · by research overlap
- David H Raulet$25,800,180
- Elcin Unal$10,790,899
- Jillian Banfield$6,262,061
- Nilabh Shastri$19,407,030
- Christopher James Nicolai$76,373
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorRegulatory T-LymphocyteImmuneNeoplastic CellCd4 Positive T LymphocytesT-LymphocyteCellsCancer TherapyMalignant NeoplasmsResponseCell PhysiologyCancer ImmunotherapyAntibodiesGeneticImmunosuppressionMigrationCytokineCancer ControlCd8-Positive T-LymphocytesAnti-CancerImmunotherapyMediatingProductionTumor Immunity
Grant awards (6)
Tregulatory cell-mediated suppression of tumor elimination by NK cells and CD4 T cells$663,340
R01 · FY2025 · CA
Immunosuppressive mechanisms of intratumoral regulatory T cells$618,928
R01 · FY2025 · CA · contact PI
Reversing cancer immunosuppression using attenuated Listeria monocytogenes$473,641
R01 · FY2025 · CA
Testing the contribution of ex-Tregs to autoimmunity and cancer immunity$441,202
R21 · FY2025 · AI · contact PI
Reversing cancer immunosuppression using attenuated Listeria monocytogenes$473,641
R01 · FY2024 · CA
Engineering precision cancer immunotherapy$2,355,000
DP2 · FY2019 · CA · contact PI